Updated NETs Clinical Trials

1. Study on Genomic and Methylation Markers in Small Cell and Large Cell Lung Cancer for Chemo-Immunotherapy Resistance Prediction

   Conditions: Small Cell Lung Cancer; Large Cell Neuroendocrine (NE) Tumors; Treatment Failure; Biomarkers / Blood; Biomarkers; Immunotherapy Interventions: Drug: Carboplatin/Cisplatin -Etoposide - Atezolizumab Sponsors: Oncology Center of Biochemical Education And Research; National and Kapodistrian University of Athens; Icahn School of Medicine at Mount Sinai; Sotiria General Hospital Not yet recruiting

2. Serum and Corporal Irisin Level and Its Correlation With Erectile Function in Diabetic Obese Patients

   Conditions: Serum and Corporal Irisin in Diabetic Patients With Erectile Dysfunction Interventions: Procedure: Serum and corporal irisin Sponsors: Assiut University Not yet recruiting

3. Window on the Brain

   Conditions: Disorders of Consciousness Interventions: Device: Ultrasound technique for diagnosis; Focused Ultrasound Stimulation for intervention Sponsors: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta; IRCCS Istituto delle Scienze Neurologiche di Bologna; S.Anna Rehabilitation Institute; IRCCS Centro Neurolesi Bonino Pulejo Recruiting

4. Negative Emotionality and Epigenetics During Puberty

   Conditions: Puberty; Healthy; Stress Interventions: Behavioral: Stress Sponsors: International Research Training Group 2804; University Hospital Tuebingen; Uppsala University; German Research Foundation Recruiting

5. Ivocizumab in the Treatment of Multiple Advanced Tumors

   Conditions: Pheochromocytoma/Paraganglioma; Rhabdomyosarcoma; Paget Disease, Extramammary; Renal Angiomyolipoma; Perivascular Epithelioid Cell Tumor, Malignant; Sarcoma Interventions: Drug: Ivocizumab Sponsors: Fudan University Not yet recruiting

6. Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors

   Conditions: Pituitary Adenoma; Pituitary Neuroendocrine Tumor Interventions: Drug: Hormone replacement therapy; Drug: Placebo Sponsors: Beijing Tiantan Hospital Not yet recruiting

7. Effect of Transversus Abdominis Plan Block and Recto-Intercostal Fascial Plan Block in Laparoscopic Cholecystectomy

   Conditions: Postoperative Pain Interventions: Procedure: Group T (Transversus Abmoninis Plane Block); Procedure: Group R (Rectus-Intercostal Fascial Plane Block) Sponsors: Hitit University Recruiting

8. ML Decision Model for G-NEC Adjuvant Therapy

   Conditions: Gastric Neuroendocrine Carcinoma (G-NEC); Postoperative Adjuvant Therapy for G-NEC; Survival Outcomes; Machine Learning Sponsors: Chang-Ming Huang, Prof. Completed

9. Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

   Conditions: Advanced Solid Tumor; Metastatic Solid Tumor; Refractory Solid Tumor; Cancer; Lung Cancer; Triple Negative Breast Cancer; Breast Neoplasms; Neuroendocrine Tumors; Neuroendocrine Carcinoma Interventions: Drug: CID-078 Monotherapy Sponsors: Circle Pharma Recruiting

10. MSD Belzutifan PAS

    Conditions: Von Hippel Lindau Disease Interventions: Other: Belzutifan Sponsors: Merck Sharp & Dohme LLC Withdrawn

11. Romosozumab As an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

    Conditions: FHA (Functional Hypothalamic Amenorrhea) Interventions: Drug: Romosozumab; Drug: Placebo; Drug: Zoledronic acid Sponsors: Massachusetts General Hospital Not yet recruiting

12. Behavioral Therapy for Crohn's Disease

    Conditions: Crohn's Disease Interventions: Behavioral: Primary Intervention for Combination Therapy - IBD Coping Strategies Program; Behavioral: Time and Attention Control - IBD Support Program Sponsors: Icahn School of Medicine at Mount Sinai; The Leona M. and Harry B. Helmsley Charitable Trust Recruiting

13. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

    Conditions: Pancreatic Ductal Adenocarcinoma; Cholangiocarcinoma; Gastric Cancer; Bladder Cancer; Hepatocellular Carcinoma; Pheochromocytoma; Ovarian Cancer Interventions: Drug: [18F]FAPI-74; Drug: [18F]FDG Sponsors: National Cancer Institute (NCI) Not yet recruiting

14. Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

    Conditions: Extensive Stage Small Cell Lung Cancer Interventions: Drug: Tarlatamab Sponsors: Amgen Recruiting

15. NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

    Conditions: Non-squamous Metastatic Non-Small-Cell Lung Carcinoma Sponsors: AstraZeneca Recruiting

16. [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

    Conditions: Head and Neck Tumors; Kidney Cancers; Small Cell Lung Cancers; Pheochromocytoma/Paragangliomas; Gastrointestinal Neuroendocrine Tumors; Somatostatin Receptor Positive Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Not yet recruiting

17. Androgen Effects on the Reproductive Neuroendocrine Axis

    Conditions: Transgenderism; Reproductive Issues Interventions: Drug: Testosterone Cypionate 50 MG/ML Injectable Solution Sponsors: University of California, San Diego; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Recruiting

18. Hereditary Pheochromocytoma Assessment of Tumour Immunologies

    Conditions: Pheochromocytoma; Paraganglioma Interventions: Procedure: Venepuncture; Procedure: Venepuncture Sponsors: Radboud University Medical Center Recruiting

19. Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

    Conditions: NET; Lymphoma; Solid Tumor, Childhood; Somatostatin Receptor Positive; CNS Tumor Interventions: Drug: Lutetium Lu 177-Edotreotide; Other: Amino Acid Solution Sponsors: ITM Solucin GmbH Not yet recruiting

20. Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

    Conditions: Somatostatin Receptor Positive; Gastrointestinal Neuroendocrine Tumors; Pheochromocytoma; Paragangliomas Interventions: Drug: 68Ga-DOTATATE; Drug: [203Pb]VMT-alpha-NET; Drug: [212Pb]VMT-alpha-NET Sponsors: National Cancer Institute (NCI) Not yet recruiting

21. A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

    Conditions: Carcinoma, Neuroendocrine; Tumor, Neuroendocrine; Tumors, Neuroendocrine; Neuroendocrine; Carcinoma; Small Cell; Receptors Interventions: Drug: Belinostat; Drug: Cisplatin; Drug: Etoposide Sponsors: National Cancer Institute (NCI) Not yet recruiting

22. NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

    Conditions: Metastatic Neuroendocrine Prostate Cancer Interventions: Drug: [68Ga]Ga-PSMA-11; Drug: [68Ga]GA-DOTA-TATE; Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-PSMA-617; Drug: [177Lu]Lu-DOTA-TATE; Drug: [177Lu]Lu-NeoB; Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,; Drug: Gonadotropin-releasing hormone (GnRH) analogues; Drug: GnRH antagonists; Drug: Antiemetics & antinauseants; Drug: Metoclopramide Sponsors: Novartis Pharmaceuticals Recruiting

23. A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

    Conditions: Basal Ganglia Germinoma; Central Nervous System Germinoma; Diabetes Insipidus; Pineal Region Germinoma; Suprasellar Germinoma; Thalamic Germinoma Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Procedure: Biospecimen Collection; Drug: Carboplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy; Procedure: Lumbar Puncture; Procedure: Magnetic Resonance Imaging; Other: Questionnaire Administration; Procedure: Surgical Procedure Sponsors: Children's Oncology Group Recruiting

24. A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

    Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Acromegaly Sponsors: Ipsen Recruiting

25. A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan

    Conditions: Neuroendocrine Neoplasms Interventions: Drug: [68Ga]Ga-DOTA-TATE; Drug: 68Ge/68Ga Generator Sponsors: Novartis Pharmaceuticals; Eckert & Ziegler Radiopharma GmbH Recruiting

26. Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

    Conditions: Small Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract Interventions: Drug: Lurbinectedin; Drug: Avelumab Sponsors: National Cancer Institute (NCI) Recruiting

27. Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

    Conditions: Metastatic Chondrosarcoma; Locally Advanced Chondrosarcoma; Metastatic Sinonasal Adenocarcinoma; Locally Advanced Sinonasal Adenocarcinoma; Metastatic Large-cell Neuroendocrine Carcinoma; Locally Advanced Large-cell Neuroendocrine Carcinoma; Metastatic Olfactory Neuroblastoma; Locally Advanced Olfactory Neuroblastoma; Metastatic Sinonasal Undifferentiated Carcinoma; Locally Advanced Sinonasal Undifferentiated Carcinoma Interventions: Drug: Enasidenib Sponsors: National Cancer Institute (NCI) Recruiting

28. Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

    Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Recruiting

29. A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

    Conditions: Advanced Neuroendocrine Carcinoma Interventions: Drug: LBL-024 for Injection; Drug: Etoposide Injection; Drug: Carboplatin Injection; Drug: Atezolizumab injection; Drug: Cisplatin injection Sponsors: Nanjing Leads Biolabs Co.,Ltd Recruiting

30. DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

    Conditions: Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin Sponsors: Boehringer Ingelheim Recruiting

31. Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Device: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT); Device: Photon Emission Tomography / CT (PET/CT); Drug: 64Cu-Dotatate; Drug: 177Lu-Dotatate Sponsors: University of Wisconsin, Madison Recruiting

32. Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

    Conditions: Neuroendocrine Carcinomas; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Carcinoma, Adrenocortical; Carcinoma, Adrenal Cortical Interventions: Drug: ADCT-701 Sponsors: National Cancer Institute (NCI) Recruiting

33. A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer

    Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: [89Zr]Zr-BI 764532 Sponsors: Boehringer Ingelheim Recruiting

34. Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

    Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma; Unresectable Merkel Cell Carcinoma Interventions: Drug: Avelumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Tuvusertib Sponsors: National Cancer Institute (NCI) Recruiting

35. HTL0039732 in Participants with Advanced Solid Tumours

    Conditions: Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Colorectal Neoplasms; Pancreatic Neoplasms; Lung Neoplasms; Urinary Bladder Neoplasms; Mesothelioma, Malignant; Uterine Cervical Neoplasms; Kidney Neoplasms; Sarcoma; Pheochromocytomas Interventions: Drug: HTL0039732 Capsules; Drug: HTL0039732 Capsules and atezolizumab infusion Sponsors: Cancer Research UK; Nxera Pharma UK Limited Recruiting

36. Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

    Conditions: Neuroendocrine Tumors; Lung Neuroendocrine Neoplasm; Thymus Neoplasms Interventions: Drug: 177Lu-edotreotide; Drug: Everolimus Sponsors: Grupo Espanol de Tumores Neuroendocrinos; ITM Oncologics GmbH; MFAR Recruiting

37. DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

    Conditions: Small Cell Lung Carcinoma; Neuroendocrine Neoplasms Interventions: Drug: BI 764532, formulation 1; Drug: BI 764532, formulation 2 Sponsors: Boehringer Ingelheim Active, not recruiting

38. A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

    Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: Obrixtamig; Drug: Ezabenlimab Sponsors: Boehringer Ingelheim Recruiting

39. Paraphilic Disorders and Other Conditions with Risk for Sexual Violence: a Case-control Study

    Conditions: Paraphilic Disorders; Sexual Addiction; Parasomnia Interventions: Behavioral: Treatment as usual Sponsors: Region Stockholm; Umeå University Recruiting

40. Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

    Conditions: Metastatic Midgut Neuroendocrine Tumor; Metastatic Midgut Neuroendocrine Tumor G1; Metastatic Midgut Neuroendocrine Tumor G2; Unresectable Midgut Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI) Recruiting

41. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

    Conditions: Metastatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine Sponsors: National Cancer Institute (NCI) Recruiting

42. Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients with Vestibular Schwannomas

    Conditions: Vestibular Schwannoma Interventions: Procedure: Microsurgical resection of VS; Radiation: Stereotactic radiosurgery; Other: PREHAB Sponsors: Medical College of Wisconsin Recruiting

43. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    Conditions: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Radiation: Gallium Ga 68-DOTATATE; Drug: Lutetium Lu 177 Dotatate; Procedure: Positron Emission Tomography Sponsors: National Cancer Institute (NCI) Recruiting

44. Mechanisms of Depression and Anhedonia in Adolescents: Linking Sleep to Reward- and Stress-Related Brain Function

    Conditions: Depression in Adolescence Interventions: Behavioral: Sleep extension and advance; Behavioral: Regular sleep duration and timing Sponsors: University of Oregon; Oregon Research Institute; University of Pittsburgh; National Institute of Mental Health (NIMH) Recruiting

45. Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

    Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Pancreatic Neoplasm; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Stage IV Pancreatic Neuroendocrine Tumor AJCC v8; Unresectable Pancreatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI) Recruiting

46. A Study of PT217 in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

    Conditions: Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC); Neuroendocrine Carcinomas (NEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) Interventions: Drug: PT217; Drug: Carboplatin + Etoposide; Drug: Paclitaxel.; Drug: Atezolizumab Sponsors: Phanes Therapeutics; Hoffmann-La Roche Recruiting

47. A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Conditions: Small Cell Lung Cancer; Neuroendocrine Carcinoma Interventions: Drug: RO7616789; Drug: Tocilizumab Sponsors: Hoffmann-La Roche Recruiting

48. Neoadjuvant PRRT With Y-90-DOTATOC in pNET

    Conditions: Pancreatic Neuroendocrine Tumor Interventions: Drug: peptide receptor radionuclide therapy with Y-90-DOTATOC Sponsors: European Institute of Oncology; Agenzia Italiana del Farmaco Terminated

49. Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

    Conditions: Neuroendocrine Tumors; Frailty; Chemotherapy Effect Interventions: Drug: Temozolomide capsule Sponsors: European Institute of Oncology Recruiting

50. Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    Conditions: GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET Interventions: Drug: RYZ101; Drug: Everolimus; Drug: Sunitinib; Drug: Octreotide; Drug: Lanreotide Sponsors: RayzeBio, Inc. Recruiting